Peer-reviewed veterinary case report
Kidney tests in dogs with Addison's on long-term hormone therapy
By Casado Díaz, Jose I et al.·Published in The Veterinary record·2022·Clinic for Small Animal Internal Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of symmetric dimethylarginine and creatinine in dogs with primary hypoadrenocorticism receiving long-term mineralocorticoid replacement therapy.
- Species:
- dog
Plain-English summary
A group of dogs with primary hypoadrenocorticism (a condition where the adrenal glands don't produce enough hormones) were monitored for kidney function while receiving long-term hormone replacement therapy. Most of the 32 dogs showed normal kidney function, but three dogs had elevated levels of certain markers indicating chronic kidney disease (CKD). These findings suggest that dogs with this condition on long-term treatment might be at a higher risk for kidney problems than other dogs. Regular check-ups and blood tests can help catch any issues early.
People also search for: dog kidney disease symptoms · primary hypoadrenocorticism treatment · elevated creatinine in dogs
Abstract
OBJECTIVES: To investigate kidney function by determining serum symmetric dimethylarginine (sSDMA) and serum creatinine (sCr) concentrations in dogs with primary hypoadrenocorticism (PH) receiving long-term mineralocorticoid replacement therapy. METHODS: Dogs with PH receiving a minimum of 12 months of either desoxycorticosterone pivalate or fludrocortisone acetate were included in the study provided that banked frozen serum samples were available for sSDMA analysis. sCr concentrations were retrieved from the medical records. In dogs still alive and presented for regular re-evaluations and in newly diagnosed patients, blood was prospectively collected for sSDMA and sCr determination. RESULTS: Thirty-two dogs met the inclusion criteria. The treatment time ranged from 12 to 146 months after initial diagnosis (median, 55.5 months). The majority of dogs had normal sSDMA and sCr concentrations throughout the hormone replacement treatment. Both sSDMA and sCr concentrations were persistently elevated in three of 32 dogs. Further workup confirmed chronic kidney disease (CKD) in all three dogs. CONCLUSIONS: Based on these data, the prevalence of CKD could be higher in dogs with PH receiving long-term mineralocorticoid replacement treatment than in the general dog population. However, additional studies with a larger number of dogs are needed to confirm it.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33870518/